相关实验视频
Updated: Feb 4, 2026

04:08
Metacarpal Small Incision for Carpal Tunnel Syndrome
Published on: April 5, 2024
1.4K
手管道释放的自付费用
Derrick W Williams1, Philip Blazar2,3, Kyra A Benavent3
1Department of Orthopaedic Surgery, Mayo Clinic, Rochester, MN.
Journal of hand surgery global online
|February 2, 2026
概括
随着手腕道释放 (CTR) 手术的自付费用在增加. 拉丁裔种族和糖尿病等因素可以降低成本,而缺乏二次保险或在较小的房间进行手术会增加患者的费用.
科学领域:
- 医疗保健经济学 医疗保健经济学
- 外科手术的结果
- 患者的财务责任.
背景情况:
- 自付费用 (OOPC) 的增长速度快于整体医疗费用.
- 带道释放 (CTR) 在不同的麻醉协议的不同环境中进行.
- 对CTR的OOPCs可以影响患者的选择和他们对保险价值的看法.
研究的目的:
- 为了确定与手腕道释放手术后的自付费用相关的因素.
- 了解CTR对患者的财务影响.
- 为了告知有关手术选择的共享决策.
主要方法:
- 在2019年至2022年间对808名接受CTR的患者进行了回顾性分析.
- 定义OOPC是指在初级和二级保险后,患者收取的费用.
- 多变量逻辑回归用于识别相关因素.
主要成果:
- 西班牙裔种族和糖尿病是对OOPC的保护因素.
- 缺少二次保险,小程序室设置和州外居住是OOPC的风险因素.
- 该队列的平均年龄为61.7岁,66%是女性,79%是白人,100%有保险.
结论:
- 患者面临越来越多的医疗保健财务负担.
- 这些发现可以帮助外科医生与患者讨论可修改的选择,如手术设置和麻醉等.
- 了解OOPC因素对于患者的财务咨询至关重要.
相关概念视频
Energy-releasing Steps of Glycolysis
146.8K
Glycolysis is divided into two phases based on whether energy is utilized or released. While the first phase consumes ATP, the second phase produces energy in the form of ATP and NADH. The energy is released over a sequence of reactions that turns G3P into pyruvate. The energy-releasing phase—steps 6-10 of glycolysis—occurs twice, once for each of the two 3-carbon sugars produced during steps 1-5 of the first phase.
The first energy-releasing step—the 6th step of glycolysis...
The first energy-releasing step—the 6th step of glycolysis...
146.8K
ATP Energy Storage and Release
14.4K
ATP is a highly unstable molecule. Unless quickly used to perform work, ATP spontaneously dissociates into ADP and inorganic phosphate (Pi), and the free energy released during this process is lost as heat. The energy released by ATP hydrolysis is used to perform work inside the cell and depends on a strategy called energy coupling. Cells couple the exergonic reaction of ATP hydrolysis with endergonic reactions, allowing them to proceed.
One example of energy coupling using ATP involves a...
One example of energy coupling using ATP involves a...
14.4K
Drugs Affecting Neurotransmitter Release or Uptake
1.6K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.6K
In Vitro Drug Release Testing: Overview, Development and Validation
343
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
343
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
908
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
908
tRNA Activation
22.9K
Aminoacyl-tRNA synthetases are present in both eukaryotes and bacteria. Though eukaryotes have 20 different aminoacyl-tRNA synthetases to couple to 20 amino acids, many bacteria do not have genes for all of these aminoacyl-tRNA synthetases. Despite this, they still use all 20 amino acids to synthesize their proteins. For instance, some bacteria do not have the gene encoding the enzyme that couples glutamine with its partner tRNA. In these organisms, one enzyme adds glutamic acid to all of the...
22.9K

